-
Mashup Score: 84
The addition of sabatolimab to hypomethylating agents in this study did not result in a significant improvement in complete response rates or progression-free survival. Sabatolimab had a manageable safety in most patients with higher-risk myelodysplastic syndromes. A randomised phase 3 trial is ongoing to assess the potential benefit of sabatolimab plus azacitidine on overall survival in this setting.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Data-Driven Analysis Harmonizes 2022 WHO, ICC Classifications of Myelodysplastic Syndromes | ASH Clinical News | American Society of Hematology - 5 month(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. In 2022, the World Health Organization (WHO) and the International Consensus Classification (ICC) introduced gene mutations and chromosomal abnormalities into their distinct classifications of myelodysplastic syndromes (MDS). Now, new results demonstrate that a data-driven approach based on advanced statistical methods can generate a harmonization of the two systems. Luca Lanino, MD, of Humanitas Clinical and Research Center in
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Spotlight on lower-risk MDS - 5 month(s) ago
In this Spotlight On Lower-risk MDS, learn about MDS risk stratification & classification, recognizing ESA failure, and treatment beyond ESAs
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Spotlight on lower-risk MDS - 5 month(s) ago
In this Spotlight On Lower-risk MDS, learn about MDS risk stratification & classification, recognizing ESA failure, and treatment beyond ESAs
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 55New Developments in Risk Stratification and Management of High-Risk and Low-Risk MDS - 6 month(s) ago
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
Senior author of the study and Yale Cancer Center expert Amer Zeidan , MBBS, says the results showed that imetelstat, a first-in-class telomerase inhibitor,
Source: medicine.yale.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 82
The addition of sabatolimab to hypomethylating agents in this study did not result in a significant improvement in complete response rates or progression-free survival. Sabatolimab had a manageable safety in most patients with higher-risk myelodysplastic syndromes. A randomised phase 3 trial is ongoing to assess the potential benefit of sabatolimab plus azacitidine on overall survival in this setting.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Dr Zeidan on Classification and Treatment Updates in MDS - 6 month(s) ago
Amer Zeidan, MBBS, discusses classification and treatment updates for patients with myelodysplastic syndrome.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Spotlight on lower-risk MDS - 6 month(s) ago
In this Spotlight On Lower-risk MDS, learn about MDS risk stratification & classification, recognizing ESA failure, and treatment beyond ESAs
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 21Immune Checkpoint Inhibition and Novel Therapies for Myelodysplastic Syndromes/Neoplasms - 6 month(s) ago
Immune Checkpoint Inhibition and Novel Therapies for Myelodysplastic Syndromes/Neoplasms
Source: www.vumedi.comCategories: General Medicine News, Hem/OncsTweet
Our newest paper in @TheLancetHaem of Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk #MDSsm (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Haematology https://t.co/3cndkMli8H